HUTCHMED (China) Limited (HCM)
NASDAQ: HCM · Real-Time Price · USD
15.97
-0.03 (-0.19%)
At close: Aug 14, 2025, 4:00 PM
15.87
-0.10 (-0.63%)
After-hours: Aug 14, 2025, 4:10 PM EDT
HUTCHMED (China) Revenue
HUTCHMED (China) had revenue of $277.68M in the half year ending June 30, 2025, a decrease of -47.89%. This brings the company's revenue in the last twelve months to $602.20M, down -1.41% year-over-year. In the year 2024, HUTCHMED (China) had annual revenue of $630.20M, down -24.80%.
Revenue (ttm)
$602.20M
Revenue Growth
-1.41%
P/S Ratio
4.52
Revenue / Employee
$332,522
Employees
1,811
Market Cap
2.72B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 630.20M | -207.80M | -24.80% |
| Dec 31, 2023 | 838.00M | 411.59M | 96.52% |
| Dec 31, 2022 | 426.41M | 70.28M | 19.73% |
| Dec 31, 2021 | 356.13M | 128.15M | 56.21% |
| Dec 31, 2020 | 227.98M | 23.09M | 11.27% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
HCM News
- 6 days ago - HUTCHMED (China) Limited (HCM) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - HUTCHMED to Announce 2025 Half-Year Financial Results - GlobeNewsWire
- 6 weeks ago - HUTCHMED Announces China Approval for ORPATHYS® in Combination with TAGRISSO® for the Treatment of Lung Cancer Patients with MET Amplification After Progression on First-Line EGFR Inhibitor Therapy - GlobeNewsWire
- 2 months ago - HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Renal Cell Carcinoma - GlobeNewsWire
- 2 months ago - HUTCHMED Highlights SACHI Phase III Study Data Presented at the 2025 ASCO Annual Meeting - GlobeNewsWire
- 2 months ago - HUTCHMED Highlights Clinical Data to be Presented at the 2025 ASCO Annual Meeting - GlobeNewsWire
- 4 months ago - HUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2025 - GlobeNewsWire
- 4 months ago - HUTCHMED Completes Patient Enrollment of a Phase II Registration Study of Savolitinib in Gastric Cancer in China - GlobeNewsWire